Concurrent with the development of PSMA-targeted imaging, the application of PSMA-targeted radioligand therapy is an ongoing area of great potential, and several PSMA-targeted radiopharmaceuticals have been developed for the treatment of advanced prostate cancer which enable the delivery of radiation to both bone and soft tissue tumor sites. This evidence concerns the gene FOLH1 and prostate cancer.